SCHEMBL13853016

SCHEMBL13853016

CCc1ccc(NC(=O)Nc2ccc(F)cc2)c(C)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 4/20 0.58
MAPT P10636 6/20 0.55
MEN1 O00255 5/20 0.55
KMT2A Q03164 5/20 0.55
CASP3 P42574 1/20 0.55
TRPV1 Q8NER1 1/20 0.55
SENP7 Q9BQF6 1/20 0.55
RAB9A P51151 7/20 0.52
NPC1 O15118 6/20 0.52
SMN1; SMN2 Q16637 5/20 0.52
LMNA P02545 1/20 0.50
POLB P06746 2/20 0.49
MAPK1 P28482 1/20 0.49
CTDSP1 Q9GZU7 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CA9 Q16790 1/20 0.47
PKM P14618 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4117952 0.83 RAB9A (0.67) HTTMAPTMEN1KMT2ACASP3
SCHEMBL4124525 0.83 NTRK1 (0.55) HTTMAPTMEN1KMT2ARAB9A
SCHEMBL4121977 0.81 IDH1 (0.61) MAPTMEN1KMT2ATRPV1RAB9A
SCHEMBL4916645 0.80 MAPT (0.71) HTTMAPTMEN1KMT2ACASP3
SCHEMBL11419588 0.79 SMN1; SMN2 (0.47) HTTMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL4920295 0.79 MAPT (0.76) HTTMAPTMEN1KMT2ACASP3
SCHEMBL4920563 0.79 MAPT (0.56) HTTMAPTMEN1KMT2ACASP3
SCHEMBL13852829 0.79 MAPT (0.72) HTTMAPTMEN1KMT2ARAB9A
SCHEMBL11408913 0.78 L3MBTL1 (0.50) MAPTMEN1KMT2ASMN1; SMN2MAPK1
SCHEMBL4124716 0.78 RAB9A (0.56) HTTMAPTMEN1KMT2ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090118277-A1 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors NOVARTIS AG 2009-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118277-A1 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors TIE1, TEK, MATK HTT 2008/4885MAPT 1454/4885MEN1 1723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.